Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Felmetatug vedotin (Primary)
  • Indications Adenocarcinoma; Adenoid cystic carcinoma; Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Endometrial cancer; Fallopian tube cancer; Gallbladder cancer; HER2 negative breast cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors Seagen

    • Most Recent Events

    • 13 Nov 2024 According to ClinicalTrials.gov by the U.S. National Institutes of Health, the one new safety primary endpoint have been added
    • 13 Nov 2024 Planned number of patients changed from 430 to 572.
    • 13 Nov 2024 Planned End Date changed from 31 Jan 2027 to 30 Nov 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top